Patents Examined by Thomas S. Heard
  • Peptidomimetic macrocycles and formulations thereof
    Patent number: 10905739
    Abstract: Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: February 2, 2021
    Assignee: Aileron Therapeutics, Inc.
    Inventors: David Allen Annis, Krzysztof Darlak, Chris Rhodes, Sonoko Kanai, Joerg Hoernschemeyer, Michaela Grass
  • Reactive oxygen species scavengers and use for treating diseases
    Patent number: 10889572
    Abstract: A compound of Formula (I), pharmaceutically acceptable salts thereof, and individual enantiomers or diastereomers thereof. Compositions and methods useful for treatment or suppression of diseases, developmental delays and symptoms related to oxidative stress.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: January 12, 2021
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Zude Qi, Dezheng Ning, Xianbo Liu
  • Multimeric bicyclic peptide ligands
    Patent number: 10875894
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 29, 2020
    Assignee: BicycleTx Limited
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter U. Park, Punit Upadhyaya
  • Anti-CD123 antibodies and conjugates and derivatives thereof
    Patent number: 10875925
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: December 29, 2020
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Lyophilized preparation of cytotoxic dipeptides
    Patent number: 10869928
    Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 22, 2020
    Assignee: ONCOPEPTIDES AB
    Inventors: Jack Spira, Fredrik Lehmann
  • High purity oritavancin and method of producing same
    Patent number: 10864249
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: December 15, 2020
    Assignees: MELINTA THERAPEUTICS, INC., ABBVIE INC.
    Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
  • Polypeptide having the capacity to form alpha-1,3 glucosyl unit branchings on an acceptor
    Patent number: 10842808
    Abstract: Polypeptides having the ability to specifically form connections of glucosyl units in alpha 1,3 on an acceptor having at least one hydroxyl moiety are presented. The polypeptides include i) the pattern I of sequence SEQ ID NO: 1, ii) the pattern II of sequence SEQ ID NO: 2, iii) the pattern III of sequence SEQ ID NO: 3, and iv) the pattern IV of sequence SEQ ID NO: 4, or derivates from one or several of said patterns, wherein the polypeptide furthermore has an aspartic residue (D) at position 5 of the pattern II (SEQ ID NO: 2), a glutamic acid residue (E) at position 6 of the pattern III (SEQ ID NO: 3) and an aspartic acid residue (D) at position 6 of the pattern IV (SEQ ID NO: 4). Methods for producing acceptors connected to glucosyl units in alpha 1,3 using the polypeptides are also provided.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 24, 2020
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Magali Remaud-Simeon, Marlene Vuillemin, Claire Moulis, Pierre Monsan, Sandrine Morel
  • Conjugates comprising an anti-EGFR1 antibody
    Patent number: 10835606
    Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)”—S—Bi2Hii2? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: November 17, 2020
    Assignee: Tenboron Oy
    Inventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
  • Peptides derived from Kita-kyushu lung cancer antigen (KKLC1, CT83, CXorf61) and complexes comprising such peptides bound to MHC molecules
    Patent number: 10835577
    Abstract: The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 17, 2020
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Chandramouli Chillakuri, Dhaval Sangani, Graham Hood, Alina Popa
  • Polyplexes
    Patent number: 10835549
    Abstract: The present disclosure relates to compounds comprising (i) an active agent, wherein the active agent includes a charge at a predetermined pH, (ii) a polymer, wherein the polymer includes an opposite charge than the active agent at the predetermined pH; and (iii) a polyplex comprising the peptide and the polymer electrostatically bond together at the predetermined pH. In some embodiments, the active agent is a peptide, such as a peptide comprising MAPKAP kinase II inhibitory peptide, and in some embodiments the peptide includes a cell-penetrating peptide. In further embodiments, the disclosure provides methods for treating a disease or condition by administering a composition according to the present disclosure to a subject in need thereof.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: November 17, 2020
    Assignees: Vanderbilt University, The United States as Represented by the Department of Veterans Affairs
    Inventors: Craig Duvall, Brian Connor Evans, Colleen Brophy, Kyle Hocking
  • Protein stabilizing factors
    Patent number: 10806695
    Abstract: Compositions and methods are described for preventing or reducing protein loss due to protein aggregation, denaturation, and absorption to surfaces. Also described are compositions and methods for preventing or reducing the fouling or clogging of medical devices that come into contact with blood, such as catheters. Also described are methods to treat diseases caused by activation of the microvasculature.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: October 20, 2020
    Assignee: BLOODWORKS
    Inventors: Dominic W. Chung, Jose Aron Lopez, Minhua Ling, Junmei Chen, Xiaoyun Fu
  • Bicyclic peptide ligands specific for MT1-MMP
    Patent number: 10792368
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: October 6, 2020
    Assignee: BicycleRD Limited
    Inventors: Daniel Paul Teufel, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassarre
  • EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
    Patent number: 10787499
    Abstract: Certain embodiments of the invention provide epithelial cell adhesion molecule (EpCAM) binding polypeptides, as well as conjugates and CSANs comprising such polypeptides. Additionally, certain embodiments of the invention also provide methods of using such polypeptides and compounds for molecular imaging and molecularly targeted therapies.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 29, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Benjamin Hackel, Carston R. Wagner, Lawrence A. Stern, Clifford Csizmar
  • Suspension compositions of cyclosporin A for subconjunctival and periocular injection
    Patent number: 10780048
    Abstract: The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin A and in some embodiments, Form 1 or Form 2 cyclosporin A. A delivery system can be provided that includes two parts, a first part containing particles of cyclosporin and a second part containing other components that can be combined with the first part to make a suspension formulation. The suspension can be injected into the subconjunctival or other periocular space to treat ocular conditions, such as dry eye disease.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: September 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Anuradha V. Gore, Hao Hou, Chetan P. Pujara, Sesha Neervannan, Ke Wu
  • Respiratory syncytial virus (RSV) replication inhibitors
    Patent number: 10774114
    Abstract: The invention provides polypeptides interacting with the binding of the RSV phosphoprotein P with the RSV nucleoprotein N and methods of using such polypeptides in the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 15, 2020
    Assignee: FONDATION THE ARK
    Inventors: Origéne Nyanguile, Jean-François Eleouet, Marie Galloux
  • Nucleic acid condensing peptide, nucleic acid condensing peptide set, nucleic acid delivery carrier, nucleic acid delivery method, cell production method, cell detection method and kit
    Patent number: 10765761
    Abstract: According to one embodiment, a nucleic acid condensing peptide includes one terminal having a first sequence RRRRRR and another terminal having a second sequence RQRQR. Between the first sequence and the second sequence, none or one or more intermediate sequences each consisting of RRRRRR or RQRQR are included. Further, of the first sequence, the second sequence and the intermediate sequences, two or more neutral amino acids are included between any two sequences adjacent to each other.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 8, 2020
    Assignee: KABUSHIKI KAISHA TOSHIBA
    Inventors: Mitsuko Ishihara, Eiichi Akahoshi, Emi Nozaki
  • Method and pharmaceutical composition for use in the treatment of cancer
    Patent number: 10759843
    Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 1, 2020
    Inventors: Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
  • Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway
    Patent number: 10751396
    Abstract: The present invention provides compositions and methods for treating or preventing a disease or disorder associated with endothelial activation, inflammation or atherogenesis, including but not limited to cardiovascular diseases and inflammatory disorders.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 25, 2020
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventor: Xiaofeng Yang
  • Methods for covalently binding a cell surface protein and a ligand
    Patent number: 10753944
    Abstract: The present invention relates to a method for covalently binding a cell surface protein and a ligand, the ligand being capable of specifically binding to the cell surface protein, the method consisting essentially of contacting the living cells expressing the cell surface protein with the ligand comprising at least one furan moiety, thereby covalently binding the cell surface protein and the ligand.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 25, 2020
    Assignee: UNIVERSITEIT GENT
    Inventors: Annemieke Madder, Christophe Ampe, Willem Vannecke, Marleen Van Troys
  • Scorpion toxin fusion protein with enhanced skin cell proliferation effect and cosmetic composition for anti-wrinkle, enhancing skin elasticity and anti-aging comprising the same as an effective ingredient
    Patent number: 10745451
    Abstract: A fusion protein having the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 has enhanced skin cell proliferation effect. A composition includes, as an effective ingredient, the fusion protein for improving skin wrinkle, skin elasticity, and anti-aging. Because the composition has an excellent cell proliferation effect and an effect of improving skin wrinkle and enhancing skin elasticity, it is expected to be used advantageously in the field of functional cosmetics.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: August 18, 2020
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventor: Sun Kyo Lee